Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
A personalized surveillance strategy according to risk stratification appears to be safe in the management of patients with serrated polyposis syndrome, reducing colonoscopy burden without risking an increased colorectal cancer incidence, a recent study has shown.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.
Elderly, vulnerable patients with metastatic colorectal cancer (CRC) experienced longer progression-free survival (PFS) and fewer toxicities with a reduced-dose combination chemotherapy regimen of S-1 and oxaliplatin compared with full-dose S-1 monotherapy, the phase II NORDIC9* trial showed.
People who take aspirin or direct-acting oral anticoagulants (DOACs) regularly may be more likely to get false positive results on a faecal immunochemical testing (FIT) used for screening advanced adenomas and colorectal cancer (CRC), a recent study finds.
KRAS and BRAF mutations were associated with shorter relapse-free survival in patients with stage II or III colorectal cancer treated with curative intent, particularly in patients who were also microsatellite instability (MSI)-negative, according to a recent study.
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
Discontinuation of antitumour necrosis factor (anti-TNF) therapy for perianal Crohn’s disease is highly likely to lead to relapse, with some patients even requiring defunctioning surgery, according to a study conducted across Asia.